報價延遲最少15分鐘:2026/11/04 14:31 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.10/0.04
|
|
企業價值
3.52B
|
| 資產負債 |
|
每股賬面淨值
1.44
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
803.79M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent. |
